We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 913

Court dismisses Section 8 damages appeal and grants cross-appeal
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • April 18 2018

On March 20 2018 the Federal Court of Appeal issued public reasons for its dismissal of Eli Lilly Canada Inc's appeal of a Federal Court decision that


Alexion files for leave to appeal to Supreme Court of Canada in case challenging constitutionality of PMPRB remedial powers
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • April 3 2018

On February 5, 2018, Alexion Pharmaceuticals filed an application for leave to appeal a decision of the Federal Court of Appeal (FCA


No Section 8 Liability for Valid and Infringed Patent in NEXIUM Proceeding
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • March 29 2018

What happens when a patentee is unsuccessful in a prohibition application under the Patented Medicines (Notice of Compliance) (PMNOC) Regulations


Top Developments in Canadian Employment Law in 2017
  • DLA Piper
  • Canada
  • February 26 2018

With 2017 in our rear-view mirror and with 2018 now upon us, it is time to reflect on the top developments in Canadian employment law in 2017. The


Freedom of association of physicians practising at a specialized medical centre: the Supreme Court of Canada declines to intervene
  • Lavery de Billy LLP
  • Canada
  • February 21 2018

On February 8, 2019, the Supreme Court of Canada dismissed the application by the Fédération des médecins spécialistes du Québec for leave to appeal


Pleading amendments relating to SCC decision striking down promise doctrine denied by Ontario Superior Court of Justice
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • February 6 2018

The Federal Court previously found certain claims of Canadian Patent No. 1,341,206 ("206 patent"), relating to ramipril


What’s the test? Admissibility of Expert Opinion Evidence in Certification Applications
  • McCarthy Tétrault LLP
  • Canada
  • February 2 2018

The Saskatchewan Court of Queen’s Bench in Stout v. Bayer Inc., 2017 SKQB 329 (“Stout”) confirmed that the same standard for the admissibility of


2017 Highlights in Canadian Life Sciences IP
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • January 10 2018

The year 2017 was one of the most significant years for Canadian Life Sciences IP and Regulatory Law in Canada’s history. The year saw major de


Top 10 Legal Risks for Business in 2018
  • Borden Ladner Gervais LLP
  • Canada
  • January 3 2018

Canadian business leaders and entrepreneurs are facing an economy that’s increasingly complex and unpredictable. They are not only affected by the


Recent Court of Appeal Decisions Highlight Importance of Evidence on "Significant Threat"
  • Borden Ladner Gervais LLP
  • Canada
  • December 14 2017

Forensic mental health professionals are well-acquainted with the "significant threat" threshold. Under s. 672.54 of the Criminal Code, an accused who